Profile
REVAXIS® is a 3-in-1 booster vaccine, indicated for children from six years of age, adolescents and adults as a booster following primary vaccination, that helps protect against three separate diseases: diphtheria, tetanus and poliomyelitis (polio).
Before you prescribe this vaccine please refer to the SmPC.1
Why help protect your patients with REVAXIS Vaccine?
REVAXIS helps boost protection against diphtheria, tetanus and polio in a single injection.
REVAXIS is given as part of the national immunisation programme to teenagers at around 14 years of age (school year 9), providing the fifth and final routine vaccine against tetanus, diphtheria and polio.
Usage
Presentation |
0.5 ml prefilled syringe. Available in 1 syringe packs |
---|---|
Schedule | 1 dose |
Further dose |
REVAXIS may be used as a booster following primary immunisation with inactivated or oral poliomyelitis vaccines. REVAXIS is indicated as a booster following primary vaccination. REVAXIS is not intended for primary immunisation. |
Age range | 6 years + |
References
- REVAXIS® Summary of Product Characteristics.
MAT-XU-2301123 (v2.0) Date of preparation: October 2023